Mycapssa® (octreotide delayed-release capsules; Chiasma) is now available for the long-term maintenance treatment of adult patients with acromegaly who have responded to and tolerated treatment with octreotide or lanreotide.

Mycapssa, an oral somatostatin analogue, was approved in June 2020 based on data from a placebo-controlled phase 3 trial (NCT03252353) involving 56 adults with acromegaly whose disease was biochemically controlled by injectable somatostatin analogue (octreotide or lanreotide) based upon levels of insulin-like growth factor-1 (IGF-1). Findings showed that a greater proportion of patients treated with Mycapssa had maintained their biochemical response at 9 months compared with placebo (58% vs 19%). Among those treated with Mycapssa, 25% required discontinuation and treatment with other somatostatin analogues at some point during the study. 

Related Articles

Mycapssa delayed-release capsules should be taken on an empty stomach at least 1 hour before or at least 2 hours after a meal as administration with food led to an approximate 90% decrease in the rate and extent of absorption, according to pharmacokinetic data. Dosage should be titrated based on insulin-like growth factor 1 (IGF-1) levels and the patient’s signs and symptoms. Each delayed-release capsule contains 20mg of octreotide and is supplied in 28-count wallets.

Additionally, to help patients gain access to the treatment, the Company is offering the Chiasma Access & Patient Support (CAPS) Program.

For more information visit


Chiasma announces US commercial launch and availability of Mycapssa®, the first and only oral somatostatin analog for patients with acromegaly. Accessed September 1, 2020.